Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development.

Cancer treatment reviews - 1 Nov 2024

Corvaja Carla, Passaro Antonio, Attili Ilaria, Aliaga Pamela Trillo, Spitaleri Gianluca, Signore Ester Del, de Marinis Filippo

Abstract excerpt

Third-generation EGFR tyrosine kinase inhibitor (TKIs) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations, with improved long-term outcomes compared to first-generation TKIs. Nevertheless, disease progression inevitably occurs, limiting osimertinib long-term efficacy. Indeed, the molecular biology underlying acquired resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 39366135
DOI: 10.1016/j.ctrv.2024.102824

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development.PMID 39366135Read ↗

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Semantic proximity Read ↗

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.Semantic proximity Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical reviewSemantic proximity Read ↗

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIsSemantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC.Semantic proximity Read ↗

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read ↗

The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.Semantic proximity Read ↗

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.